Prothena (NASDAQ:PRTA) is a biotechnology company focused on discovering and developing novel therapies in the field of neuroscience. Its mission centers on leveraging deep scientific insights to advance the treatment of diseases characterized by misfolded proteins, such as amyloidosis and Parkinson's disease. Prothena's pipeline showcases a range of therapies aimed at addressing some of the most challenging neurodegenerative diseases, with projects spanning from early discovery to late-stage clinical trials. The objectives of Prothena are to deliver innovative treatments that can significantly improve patients' lives while advancing the understanding of the underlying biology of these complex diseases. Through a commitment to science and innovation, Prothena aims to lead the way in developing next-generation therapies that target the root causes of neurodegenerative diseases, offering hope to patients and families affected by these conditions.